At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
GBT440 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
In Brief
A Phase 2 clinical trial evaluating GBT440 and Placebo for Idiopathic Pulmonary Fibrosis and Hypoxemia. Completed, enrolled 39 participants across 12 sites.
Detailed Summary
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis, Hypoxemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
First PostedJul 2016
Primary CompletionSep 2017
Study CompletionNov 2017
TodayJul 2026
First PostedJul 27, 2016
Enrollment StartJun 1, 2016
Primary CompletionSep 1, 2017
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.9 years ago
Interventions
GBT440drug
Capsules which contain GBT440 drug substance in Swedish orange
Placebodrug
Placebo capsules